August 27, 2023ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)183 citationsOpen Access
Timing of Complete Revascularization with Multivessel PCI for Myocardial Infarction
Key Points
- To compare the efficacy and safety of immediate multivessel PCI versus staged multivessel PCI in hemodynamically stable patients presenting with STEMI and multivessel coronary artery disease.
- Randomized noninferiority clinical trial (MULTISTARS AMI, NCT03135275) evaluating hemodynamically stable patients with STEMI and multivessel coronary artery disease.
- Patients underwent either immediate multivessel PCI or staged multivessel PCI.
- Follow-up assessed a composite endpoint of all-cause mortality, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or heart failure hospitalization at 1 year.
- Immediate multivessel PCI met noninferiority criteria relative to staged multivessel PCI for the primary composite endpoint at 1 year (detailed event rates, hazard ratios, 95% CIs, and p-values not reported in the abstract).
Abstract
Among patients in hemodynamically stable condition with STEMI and multivessel coronary artery disease, immediate multivessel PCI was noninferior to staged multivessel PCI with respect to the risk of death from any cause, nonfatal myocardial infarction, stroke, unplanned ischemia-driven revascularization, or hospitalization for heart failure at 1 year. (Supported by Boston Scientific; MULTISTARS AMI ClinicalTrials.gov number, NCT03135275.).
Expert Takes1 quote
“The key message of the MULTISTARS-AMI trial is that we could show that in patients with STEMI and multivessel disease, immediate multivessel PCI is noninferior to staged multi-vessel PCI based on the 1-year risk for the composite of all cause death, non-fatal myocardial infarction, stroke, unplan...”
Medscape CardiologyView source
Cite This Study
Stähli et al. (2023) studied this question.